Transphorm, Inc. (Nasdaq: TGAN)
Julie & Holleman LLP is investigating the proposed sale of Transphorm, Inc. (Nasdaq: TGAN) to Renesas Electronics Corporation. Julie & Holleman believes the $5.10 per share deal price may be unfair, and the firm has identified potential conflicts of interest.
For a free consultation, please fill out the form below, or contact partner W. Scott Holleman at (917) 325-3798 or scott@julieholleman.com. There is no cost or obligation to you.
Transphorm is a global leader in the new wave of semiconductors. It designs and manufactures high performance and high reliability gallium nitride (“GaN”) semiconductors for high voltage power conversion applications. GaN semiconductors have the potential to replace traditional silicon-based semiconductors and, thus, have extraordinary commercial potential.
Based on Transphorm’s leader status in an emerging field, Wall Street analysts have raved about the company’s potential. Analysts have even established 1-year price targets as high as $8 per share, with an average target of $5.36 per share.
Despite its immense growth prospects, Transphorm announced on January 11, 2024 that it had agreed to be acquired by Renesas for $5.10 per share. When the acquisition closes, which is expected in the second half of 2024, current Transphorm shareholders will lose their stock in exchange for the sale price.
Julie & Holleman, a firm with extensive experience in mergers and acquisitions litigation, is concerned not only about the unfair price being offered, but also about potential conflicts of interest. In particular, private equity behemoth KKR owns approximately 38.6% of Transphorm and may have interests that conflict with other shareholders’ interests.
To learn more about the firm’s investigation, please fill out the form below.